Table 3.

Associations of exercise over the first 36 months after breast cancer diagnosis with total mortality and relapse/disease-specific mortality, stratified by disease stage and hormone receptor status

Total mortalityRelapse/disease-specific mortality
TotalEventsHR (95% CI)TotalEventsHR (95% CI)
Stratified by TNM a
TNM I–IIa stage3,3161663,124190
 MET-hours per weekb
  No exercise1,123671.001,044691.00
  <8.31,097440.79 (0.51–1.22)1,032500.52 (0.32–0.80)
  ≥8.31,096550.89 (0.59–1.36)1,048710.62 (0.41–0.92)
Ptrend0.3330.444
TNM IIb–III stage1,2822491,176241
 MET-hours per weekb
  No exercise5051101.004611021.00
  <8.3395730.83 (0.60–1.15)364710.57 (0.40–0.82)
  ≥8.3382660.52 (0.37–0.72)351680.45 (0.32–0.64)
Ptrend<0.001<0.002
Pinteraction0.0370.218
Stratified by ER/PR c
ER+PR+ (positive)2,4261612,308189
 MET-hours per weekb
  No exercise861701.00815801.00
  <8.3809391.41 (0.87–2.27)771460.72 (0.47–1.12)
  ≥8.3756521.32 (0.83–2.12)722630.79 (0.53–1.19)
Ptrend0.9350.540
ERPR (negative)1,3231711,213155
 MET-hours per weekb
  No exercise478761.00428621.00
  <8.3429500.58 (0.39–0.86)392450.40 (0.25–0.63)
  ≥8.3416450.40 (0.29–0.59)393480.36 (0.24–0.56)
Ptrend<0.0010.002
ER+PR/ERPR+ (mixed)9868791194
 MET-hours per weekb
  No exercise338311.00308281.00
  <8.3299280.78 (0.42–1.43)282320.62 (0.32–1.23)
  ≥8.3349280.67 (0.36–1.22)321340.51 (0.27–1.00)
Ptrend0.0510.166
Pinteraction0.0040.375
  • aAdjusted for date of birth, BMI at baseline, waist-to-hip ratio at baseline, menopausal status, income, education, QOL, cruciferous vegetable intake, soy protein intake, tea consumption, chemotherapy, radiotherapy, tamoxifen use, and ER/PR receptor status.

  • bExercise was treated as a time-dependent variable.

  • cFurther adjusted for TNM status instead of ER/PR receptor status.